If USAMRIID can't get funding then no one else can.
They funded EbolaCide1, now EbolaCide2 is pending and USAMRIID is preparing a publication in a major medical journal. Surely they will consider EbolaCide2 worthy of advancement otherwise why bother publishing about EbolaCide1!